Risk model based chemotherapy-induced nausea and vomiting (CINV) prophylaxis is the provision of an antiemetic regimen based on a combination of patient-centered factors as well as treatment factors for the determination of CINV risk. Individual risk scores for acute and delayed CINV are calculated according to predictors identified, including younger age, history of motion or morning sickness, low daily alcohol consumptions, patient expectation of having CINV, emesis in previous chemotherapy cycles, and receiving platinum- or anthracycline-based chemotherapy. Patients at low risk by the model were given prophylaxis for a moderately emetic regimen, and patients at high risk received prophylaxis recommended for highly emetic regimens.

Clemons, M., Bouganim, N., Smith, S., Mazzarello, S., Vandermeer, L., Segal, R., . . . Dranitsaris, G. (2016). Risk model-guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early-stage breast cancer: A randomized clinical trial. JAMA Oncology, 2, 225–231. doi:10.1001/jamaoncol.2015.3730